Operational Update: Aurora Cannabis Exceeds 7,700 Registered Patients, Continues Rapid Sales Growth

 CSE: ACB

VANCOUVER, Sept. 6, 2016 /CNW/ - Aurora Cannabis Inc. (CSE: ACB) (FRANKFURT: 21P) (WKN: A1C4WM) (OTCQB: ACBFF) ("Aurora" or the "Company") is pleased to provide the following operational update.

Patient Onboarding Continues Rapid Pace

On September 2, 2016, Aurora surpassed 7,700 active registered patients, just under eight months after the Company's first sale of product. This is believed to be the fastest rate of patient registration after commencement of commercial operations achieved by any Licensed Producer.

19% Sales Growth Month-over-month

Strong sales growth continued, with total weight of dried cannabis sold reaching 147,000 grams in August, 2016, versus 124,000 grams sold the previous month. Gross revenue for the month of August, 2016 was $1.2 million, a 20% increase over July, 2016.

Upgrade and Expansion of Mother Room

The Company's production facility has just completed a substantial upgrade and expansion of its mother room, with the addition of full-spectrum LED + HID lighting and an automated irrigation system that can deliver cultivar-specific nutrient formulas. The improvements effectively double the room's plant capacity and further strengthen Aurora's commitment to full lifecycle plant health and quality.

"I am delighted with our operational performance, our proprietary technologies, and our ability to execute our goals with discipline and vision.  The Aurora Standard continues to elevate the way patient needs are being met across Canada," said Terry Booth, CEO.

About Aurora

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol "ACB".

On behalf of the Board of Directors, AURORA CANNABIS INC.

Terry Booth, CEO

This news release contains statements about the Company's expectations regarding production capacity, production yields and other aspects of its anticipated future operations that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Such factors include but are not limited to the Company's ability to obtain the necessary financing and the general impact of financial market conditions, the yield from marijuana growing operations, product demand, changes in prices of required commodities, competition, government regulations and other risks set out in the Company's management's discussion and analysis filed on SEDAR. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

We seek Safe Harbour.

SOURCE Aurora Cannabis Inc.

Cam Battley, Senior VP Communications and Medical Affairs, +1.905.864.5525, [email protected], www.auroramj.com; Marc Lakmaaker, NATIONAL Equicom, 416.848.1397, [email protected]